Literature DB >> 19590249

Decorin suppresses bone metastasis in a breast cancer cell line.

Kentaro Araki1, Hiroki Wakabayashi, Ken Shintani, Joji Morikawa, Akihiko Matsumine, Katsuyuki Kusuzaki, Akihiro Sudo, Atsumasa Uchida.   

Abstract

Decorin, the prototype of an expanding family of small leucine-rich proteoglycans, is involved in a number of cellular processes including matrix assembly, fibrillogenesis and the control of cell proliferation. In this study, we investigated the role of decorin in suppressing tumor aggressiveness and bone metastases. We used a metastatic breast cancer cell line, MDA-MB-231, to show that decorin causes marked growth suppression bothin vitro and in vivo. A cytomegaloviral vector containing the decorin transgene caused greatly reduced cell growth, motility and observed metastases. Bone metastases were decreased by >90% upon decorin transfection. These results demonstrate a novel role for decorin in the reduction or prevention of tumor metastases in this breast cancer model and could eventually lead to improved therapies for metastatic breast cancer. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590249     DOI: 10.1159/000228253

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  24 in total

Review 1.  Decorin is a devouring proteoglycan: Remodeling of intracellular catabolism via autophagy and mitophagy.

Authors:  Simone Buraschi; Thomas Neill; Renato V Iozzo
Journal:  Matrix Biol       Date:  2017-11-07       Impact factor: 11.583

2.  Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin.

Authors:  Thomas Neill; Annabel Torres; Simone Buraschi; Rick T Owens; Jan B Hoek; Raffaele Baffa; Renato V Iozzo
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

Review 3.  The ever-expanding myokinome: discovery challenges and therapeutic implications.

Authors:  Martin Whitham; Mark A Febbraio
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

4.  Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse.

Authors:  Marcin Imielinski; Sangwon Cha; Tomas Rejtar; Elizabeth A Richardson; Barry L Karger; Dennis C Sgroi
Journal:  Mol Cell Proteomics       Date:  2012-01-12       Impact factor: 5.911

5.  Biomaterial Scaffolds as Pre-metastatic Niche Mimics Systemically Alter the Primary Tumor and Tumor Microenvironment.

Authors:  Brian A Aguado; Rachel M Hartfield; Grace G Bushnell; Joseph T Decker; Samira M Azarin; Dhaval Nanavati; Matthew J Schipma; Shreyas S Rao; Robert S Oakes; Yining Zhang; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Adv Healthc Mater       Date:  2018-03-09       Impact factor: 9.933

Review 6.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

7.  Decorin deficiency promotes hepatic carcinogenesis.

Authors:  Zsolt Horváth; Ilona Kovalszky; Alexandra Fullár; Katalin Kiss; Zsuzsa Schaff; Renato V Iozzo; Kornélia Baghy
Journal:  Matrix Biol       Date:  2013-12-18       Impact factor: 11.583

Review 8.  Dichotomy of decorin activity on the insulin-like growth factor-I system.

Authors:  Andrea Morrione; Thomas Neill; Renato V Iozzo
Journal:  FEBS J       Date:  2013-02-15       Impact factor: 5.542

Review 9.  Matricellular proteins as regulators of cancer metastasis to bone.

Authors:  Timothy N Trotter; Yang Yang
Journal:  Matrix Biol       Date:  2016-01-22       Impact factor: 11.583

10.  Evaluation of antioxidant network proteins as novel prognostic biomarkers for head and neck cancer patients.

Authors:  Christina A Wicker; Vinita Takiar; Rangaswamy Suganya; Susanne M Arnold; Yolanda M Brill; Li Chen; Craig M Horbinski; Dana Napier; Joseph Valentino; Mahesh R Kudrimoti; Guoqiang Yu; Tadahide Izumi
Journal:  Oral Oncol       Date:  2020-08-12       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.